Publication | Closed Access

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Tumor ImmunologySurgical OncologyNivolumab Versus ObservationCancer ImmunosurveillanceAdjuvant ImmunotherapyMedicineImmunologyMerkel Cell CarcinomaImmune Checkpoint InhibitorCancer TreatmentImmunotherapyOncologyRadiation Oncology